

PRO-PHARMACEUTICALS ANNOUNCES COMMERCIALIZATION PLANS FOR DAVANAT® WITH YIACO MEDICAL

**YIACO Medical Represents 80 Health Care Companies
and Serves 18 countries with a Population of 400 million**

Newton, Mass. (April 7, 2008) Pro-Pharmaceuticals, Inc. (Amex: PRW), a company developing targeted therapeutic compounds to treat serious disease, today announced it has signed a Letter of Intent (LOI) with YIACO Medical Co. of Kuwait, for the commercialization of DAVANAT® for the treatment of colorectal and biliary cancer. YIACO Medical serves 18 countries and represents 80 healthcare companies in the Middle East and North Africa with a population of more than 400 million.

"The collaboration with YIACO Medical is a major step forward in our efforts to commercialize DAVANAT® on a regional basis," said Theodore Zucconi, Ph.D., President of Pro-Pharmaceuticals. "YIACO Medical provides us with an experienced partner, who enables us to achieve market penetration in major international markets."

"Through this collaboration with Pro-Pharmaceuticals, we have now gained access to a promising cancer therapy that potentially allows us to address an area of high medical importance where current therapies are clearly inadequate," said Dr. Hamed Hamadah, Chairman & Managing Director, YIACO Medical.

About DAVANAT®

DAVANAT®, the Company's lead product candidate, is a proprietary carbohydrate polymer. DAVANAT®'s mechanism of action is based upon binding to lectins on the diseased cell surface. DAVANAT® targets specific lectin receptors (Galectins) that are over-expressed on cancer cells. Current research indicates that Galectins affect cell development and play important roles in cancer, including tumor cell survival, angiogenesis and tumor metastasis.

Pro-Pharmaceuticals, Inc. – Advancing Drugs Through Glycoscience®

Pro-Pharmaceuticals is engaged in the discovery, development and commercialization of carbohydrate-based, targeted therapeutics for advanced treatment of cancer, liver, microbial and inflammatory diseases. Initially, the product pipeline is focused on developing targeted therapeutic compounds to treat cancer. The Company's technology also is being used to treat diseases such as liver and kidney fibrosis. The Company is headquartered in Newton, Mass. Additional information is available at www.pro-pharmaceuticals.com.

About YIACO Medical

YIACO Medical Co. is a Kuwait Stock Market-listed healthcare company that is focused on registering, distributing, marketing and promoting pharmaceutical products on behalf of multinational clients for the Middle East and North Africa (MENA) region. YIACO Medical has developed, through its MENA network, a series of efficient and cost effective basis to enable their clients to enjoy a positive penetration and better reach of

their product to the market. YIACO Medical currently represents (80) multinational healthcare companies in Kuwait and is a market leader in the Kuwait Pharma market for 54 years. With operations in Dubai, Egypt and Kuwait, YIACO Medical is strategically located in the region to actively provide invaluable regulatory & marketing direction/support, integrated business opportunities, strong financial holdings, excellent know-how, synergistic alliance and distinguished regional contacts to new upcoming Pharma and Biotech companies. Founded in the early 1950's, the company is headquartered in Kuwait. Additional information is available at <http://www.yiacokuwait.com/history.htm>.

FORWARD LOOKING STATEMENTS: Any statements in this news release about future expectations, plans and prospects for the Company, including without limitation statements containing the words "believes," "anticipates," "plans," "expects," and similar expressions, constitute forward-looking statements as defined in the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management's current expectations and are subject to a number of factors and uncertainties, which could cause actual results to differ materially from those described in such statements. We caution investors that actual results or business conditions may differ materially from those projected or suggested in forward-looking statements. More information about those risks and uncertainties is contained in the Company's most recent quarterly or annual report and other reports filed with the Securities and Exchange Commission. While the Company anticipates that subsequent events may cause the Company's views to change, the Company disclaims any obligation to update such forward-looking statements.

Contact: Pro-Pharmaceuticals, Inc., Anthony D. Squeglia: 617.559.0033; squeglia@pro-pharmaceuticals.com

DAVANAT and Advancing Drugs Through Glycoscience are registered trademarks of Pro-Pharmaceuticals.